VLADIVOSTOK, Russia – Russian researchers have announced a major breakthrough in oncology, unveiling a new mRNA-based cancer vaccine that showed 100 percent efficacy in preclinical trials.
The vaccine, named Enteromix, was presented at the 10th Eastern Economic Forum (EEF) in Vladivostok, where over 8,400 delegates from 75 countries gathered under the theme “The Far East: Cooperation for Peace and Prosperity.”
Tumour growth slowed by up to 80%
Developed by the Federal Medical and Biological Agency (FMBA), Enteromix was tested in multiple preclinical studies over the past three years.
According to FMBA head Veronica Skvortsova, the results were remarkable: repeated administration slowed tumour growth by 60–80 percent without triggering adverse effects.
“The vaccine is now ready for use; we are awaiting official approval,” Skvortsova said during the forum.
Targeting deadly cancers
The vaccine will initially focus on colorectal cancer, one of the world’s leading causes of cancer-related deaths.
Versions targeting glioblastoma, an aggressive brain tumour, and certain melanomas — including ocular melanoma — are also in advanced stages of development.
Unlike traditional vaccines that protect against infectious diseases, cancer vaccines like Enteromix train the immune system to recognise and destroy malignant cells.
Enteromix uses four harmless viruses to deliver RNA-based instructions that both attack tumours directly and boost the body’s natural defences.
Safer alternative to chemotherapy?
Medical experts note that therapeutic cancer vaccines generally carry fewer risks of severe side effects than chemotherapy or radiation.
In trials, Enteromix was well tolerated, adding to optimism that it could provide a safer treatment pathway.
Cancer vaccines already exist for bladder and prostate cancers, while the HPV vaccine prevents cervical and other cancers.
However, Enteromix represents part of a new generation of personalised cancer therapies designed to treat patients already battling the disease.
A global milestone in cancer research
If approved, Enteromix could transform the landscape of cancer treatment, offering new hope to millions of patients worldwide.
Its unveiling in Vladivostok underscores how innovations in biotechnology are increasingly shaping global healthcare, even from non-traditional centres of medical research.
